Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) will likely be announcing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to announce earnings of ($0.9133) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.28. On average, analysts expect Cadrenal Therapeutics to post ($3.86) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.
Cadrenal Therapeutics Stock Down 2.0%
Shares of NASDAQ:CVKD opened at $0.98 on Friday. Cadrenal Therapeutics has a 12 month low of $0.82 and a 12 month high of $13.01. The company’s 50-day moving average price is $1.09 and its two-hundred day moving average price is $3.79. The firm has a market cap of $3.50 million, a P/E ratio of -0.20 and a beta of 1.94.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Cadrenal Therapeutics
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc (NASDAQ: CVKD) is a clinical-stage biopharmaceutical company focused on developing therapies for patients who require long-term anticoagulation. The company’s lead product candidate is tecarfarin, an investigational oral anticoagulant designed for individuals with implanted mechanical heart valves and other mechanical circulatory support devices.
Tecarfarin is a vitamin K antagonist intended to address challenges associated with existing anticoagulant therapy, including drug interactions and changes in a patient’s metabolism.
Featured Stories
- Five stocks we like better than Cadrenal Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
